Katarina Miljević/LinkedIn
Jul 15, 2026, 13:43
Katarina Miljević: New Insights into Recombinant tPA and FXI Inhibition at ISTH 2026
Katarina Miljević, Postdoctoral Research Scientist at the Department of Clinical Pharmacology, Medical University of Vienna, shared a post on LinkedIn:
“I was delighted to present two posters at the ISTH 2026 Congress in Paris, highlighting research from the Department of Clinical Pharmacology MedUni Vienna, focusing on:
- Pharmacokinetic and pharmacodynamic equivalence of recombinant tPA products
- FXI inhibition with cenvacibart and its effects on hemodialysis circuit clotting
Grateful to all collaborators and co-authors who contributed to these projects.
Looking forward to the discussions and future research opportunities.”
Stay updated with Hemostasis Today.
-
Jul 15, 2026, 13:31Sandrine Meunier: ISTH 2026 Highlights Consensus on Pediatric Hemostatic Assessment
-
Jul 15, 2026, 13:20Mauricio Bordonaba: Reflecting on ISTH 2026 and Our Commitment to a Truly Free Hemophilia Life
-
Jul 15, 2026, 07:15Sandrine Horman: Back From an Inspiring Week at ISTH 2026
-
Jul 15, 2026, 06:55Christopher Devany: Great to Be Here in Paris for the ISTH 2026
-
Jul 15, 2026, 06:45Viviana Di Fabio: The Synergy Between Hematology and Hemostasis Starts with Platelets
-
Jul 15, 2026, 06:35Wolfgang Miesbach: Paediatric Phase 3 BASIS KIDS Data for Marstacimab at ISTH 2026
-
Jul 15, 2026, 06:06Marija Tashkovska: Advancing Knowledge and Clinical Practice Through ISTH 2026
-
Jul 15, 2026, 05:55Hong Chow: Where Science Meets Art at ISTH 2026
-
Jul 15, 2026, 05:47Maria Magnusson: Advancing Hemostasis and Thrombosis Through Science and Collaboration at ISTH 2026